SK279006B6 - Substituované fenylsulfonylamidopyrimidíny, spôsob - Google Patents
Substituované fenylsulfonylamidopyrimidíny, spôsob Download PDFInfo
- Publication number
- SK279006B6 SK279006B6 SK1804-92A SK180492A SK279006B6 SK 279006 B6 SK279006 B6 SK 279006B6 SK 180492 A SK180492 A SK 180492A SK 279006 B6 SK279006 B6 SK 279006B6
- Authority
- SK
- Slovakia
- Prior art keywords
- methoxyphenoxy
- tert
- benzenesulfonamide
- hydroxyethoxy
- butyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Lubricants (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Bipolar Transistors (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH176091 | 1991-06-13 | ||
CH151692 | 1992-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
SK279006B6 true SK279006B6 (sk) | 1998-05-06 |
Family
ID=25687870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1804-92A SK279006B6 (sk) | 1991-06-13 | 1992-06-12 | Substituované fenylsulfonylamidopyrimidíny, spôsob |
Country Status (34)
Country | Link |
---|---|
US (1) | US5292740A (fr) |
EP (1) | EP0526708B1 (fr) |
JP (1) | JPH0730042B2 (fr) |
KR (1) | KR100235507B1 (fr) |
AT (1) | ATE197044T1 (fr) |
AU (1) | AU653604B2 (fr) |
BG (1) | BG60831B2 (fr) |
BR (1) | BR9202219A (fr) |
CA (1) | CA2071193C (fr) |
CY (2) | CY2306B1 (fr) |
CZ (1) | CZ281434B6 (fr) |
DE (2) | DE59209872D1 (fr) |
DK (1) | DK0526708T3 (fr) |
DZ (1) | DZ1587A1 (fr) |
EE (1) | EE03028B1 (fr) |
ES (1) | ES2152222T4 (fr) |
FI (1) | FI112216B (fr) |
GR (1) | GR3035162T3 (fr) |
HU (2) | HU221203B1 (fr) |
IE (1) | IE921920A1 (fr) |
IL (1) | IL102138A (fr) |
IS (1) | IS2054B (fr) |
LU (2) | LU90976I2 (fr) |
MX (1) | MX9202747A (fr) |
NL (1) | NL300097I1 (fr) |
NO (2) | NO303826B1 (fr) |
NZ (1) | NZ243074A (fr) |
PT (1) | PT526708E (fr) |
RO (1) | RO111268B (fr) |
RU (1) | RU2086544C1 (fr) |
SG (1) | SG54209A1 (fr) |
SK (1) | SK279006B6 (fr) |
TW (1) | TW222625B (fr) |
ZA (1) | ZA924126B (fr) |
Families Citing this family (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
UA26273A (uk) * | 1989-08-30 | 1999-07-19 | Ірвін Фокс | Спосіб одержаhhя hосія із міhералу моhтморилоhіту для видалеhhя сірководhю та меркаптаhів вуглеводhів |
US5736509A (en) * | 1990-12-14 | 1998-04-07 | Texas Biotechnology Corporation | Cyclic peptide surface feature mimics of endothelin |
TW224462B (fr) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
US5378715A (en) * | 1992-02-24 | 1995-01-03 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
US5420123A (en) * | 1992-12-21 | 1995-05-30 | Bristol-Myers Squibb Company | Dibenzodiazepine endothelin antagonists |
US5352800A (en) * | 1993-03-11 | 1994-10-04 | Merck & Co., Inc. | Process for the production of a novel endothelin antagonist |
US5334598A (en) * | 1993-03-19 | 1994-08-02 | Merck & Co., Inc. | Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives |
US5767310A (en) * | 1993-03-19 | 1998-06-16 | Merck & Co., Inc. | Phenoxyphenylacetic acid derivatives |
US5401745A (en) * | 1993-03-19 | 1995-03-28 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
US5374638A (en) * | 1993-03-19 | 1994-12-20 | Merck & Co., Inc. | Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma |
US5420133A (en) * | 1993-03-19 | 1995-05-30 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
FI941826A (fi) | 1993-04-21 | 1994-10-22 | Takeda Chemical Industries Ltd | Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi |
US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
PT634175E (pt) * | 1993-07-15 | 2001-06-29 | Hoffmann La Roche | Combinacao farmaceutica que contem um inibidor do sistema renina-angiotensina e o antagonista de endotelina |
US5686478A (en) * | 1993-07-20 | 1997-11-11 | Merck & Co. Inc. | Endothelin antagonists |
US6140325A (en) * | 1993-08-19 | 2000-10-31 | Takeda Chemical Industries, Ltd. | Thienopyrimidine derivatives, their production and use |
US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
CA2173875A1 (fr) * | 1993-11-01 | 1995-05-11 | Hideyuki Saika | Antagonistes de recepteur d'endotheline |
IL111959A (en) * | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
US6268369B1 (en) | 1994-11-16 | 2001-07-31 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
PL320263A1 (en) | 1994-11-16 | 1997-09-15 | Synaptic Pharma Corp | Dihydropyrimidines and their application |
WO1996016963A1 (fr) * | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamides et leur utilisation comme medicaments |
CA2162630C (fr) * | 1994-11-25 | 2007-05-01 | Volker Breu | Sulfonamides |
CN1064965C (zh) * | 1994-11-25 | 2001-04-25 | 弗·哈夫曼-拉罗切有限公司 | 新的磺酰胺类化合物及其作为药物的用途 |
US5837708A (en) * | 1994-11-25 | 1998-11-17 | Hoffmann-La Roche Inc. | Sulphonamides |
TW313568B (fr) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
CA2208011A1 (fr) * | 1994-12-20 | 1996-06-27 | F. Hoffmann-La Roche Ag | Derives aryl- et hetaryl-sulfonamides, leur preparation et leur utilisation comme antagonistes de l'endotheline |
ES2196090T3 (es) | 1994-12-28 | 2003-12-16 | Kowa Co | Derivados pirimidinicos. |
US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
US5573762A (en) * | 1995-04-24 | 1996-11-12 | Genentech, Inc. | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy |
US5739333A (en) * | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
DE19527568A1 (de) * | 1995-07-28 | 1997-01-30 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
DE19528418A1 (de) * | 1995-08-02 | 1997-02-06 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19530032A1 (de) * | 1995-08-16 | 1997-02-20 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
JPH09124620A (ja) | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
CZ260596A3 (en) * | 1995-10-12 | 1997-12-17 | Hoffmann La Roche | Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof |
US6228861B1 (en) | 1995-11-16 | 2001-05-08 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
CN1102580C (zh) * | 1995-12-20 | 2003-03-05 | 山之内制药株式会社 | 芳基乙烯基磺酰胺衍生物及其医药组合物 |
US5977117A (en) * | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
JP2001523218A (ja) | 1996-02-20 | 2001-11-20 | ブリストル―マイヤーズ・スクイブ・カンパニー | ビフェニルイソキサゾール・スルホンアミドの製造法 |
US5958905A (en) | 1996-03-26 | 1999-09-28 | Texas Biotechnology Corporation | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin |
US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6245773B1 (en) | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
JPH11514676A (ja) * | 1996-08-09 | 1999-12-14 | メルク エンド カンパニー インコーポレーテッド | 立体選択的脱酸素化反応 |
AU4196697A (en) * | 1996-09-16 | 1998-04-14 | Dalhousie University | Use of igf-i for the treatment of polycystic kidney disease and related indications |
US5883254A (en) * | 1996-11-08 | 1999-03-16 | Hoffmann-La Roche Inc. | Process for making pyrimidine derivatives |
DE19653024A1 (de) * | 1996-12-19 | 1998-06-25 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
TW432028B (en) * | 1997-01-14 | 2001-05-01 | Merck & Co Inc | Asymmetric conjugate addition reaction using a chiral additive |
US5998625A (en) * | 1997-01-14 | 1999-12-07 | Merck & Co., Inc. | Asymmetric conjugate addition reaction using a chiral additive |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
AU6187898A (en) * | 1997-01-30 | 1998-08-25 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
HU227183B1 (en) | 1997-04-28 | 2010-09-28 | Encysive Pharmaceuticals Inc | Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders |
US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
US6022972A (en) | 1997-08-08 | 2000-02-08 | Merck & Co., Inc. | Pyridine propanoic acid derivatives |
US6410554B1 (en) | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
US6136971A (en) * | 1998-07-17 | 2000-10-24 | Roche Colorado Corporation | Preparation of sulfonamides |
US6274585B1 (en) | 1998-12-23 | 2001-08-14 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6680323B2 (en) | 1998-12-23 | 2004-01-20 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
HUP0201320A2 (en) | 1999-03-19 | 2002-08-28 | Bristol Myers Squibb Co | Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof |
DE19916719A1 (de) * | 1999-04-13 | 2000-10-19 | Basf Ag | Neue ECE-Inhibitoren, ihre Herstellung und Verwendung |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
US6720322B2 (en) * | 1999-12-22 | 2004-04-13 | Actelion Pharamceuticals Ltd. | Butyne diol derivatives |
AU3536701A (en) * | 1999-12-22 | 2001-07-03 | Actelion Pharmaceuticals Ltd | Butyne diol derivatives |
CA2395684C (fr) | 1999-12-31 | 2012-01-03 | Texas Biotechnology Corporation | Sulfonamides et leurs derives modulant l'activite de l'endotheline |
EP1254121B1 (fr) * | 2000-01-25 | 2006-02-01 | F. Hoffmann-La Roche Ag | Preparation de sulfonamides |
US6521632B2 (en) | 2000-02-11 | 2003-02-18 | Oy Juvantia Pharma Ltd | Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor |
PL357872A1 (en) * | 2000-02-11 | 2004-07-26 | Oy Juvantia Pharma Ltd | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
MY140724A (en) * | 2000-07-21 | 2010-01-15 | Actelion Pharmaceuticals Ltd | Novel arylethene-sulfonamides |
US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
NZ525614A (en) | 2000-12-18 | 2005-03-24 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
RU2004105035A (ru) * | 2001-07-20 | 2005-06-27 | Ой Ювантиа Фарма Лтд (Fi) | Соединения, полезные для лечения или профилактики заболевания, опосредованного альфа-2b-адреноцептором |
FI116940B (fi) | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
FR2831446B1 (fr) * | 2001-10-26 | 2004-03-05 | Sanofi Synthelabo | Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire |
EP2266590A3 (fr) | 2002-02-22 | 2011-04-20 | Shire LLC | Système d'administration de substances actives et méthodes de protection et d'administration de substances actives |
EP2399903A1 (fr) | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Inhibiteurs de CCR9 et leurs procédés dýutilisation |
GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
CA2412856A1 (fr) * | 2002-11-27 | 2004-05-27 | Frederic Bodin | Composition pharmaceutique pour le traitement de l'hypertension arterielle pulmonaire |
RU2329255C2 (ru) | 2002-12-02 | 2008-07-20 | Актелион Фармасьютиклз Лтд | Пиримидинсульфамиды и их использование в качестве антагонистов эндотелиальных рецепторов |
US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
TW200605867A (en) | 2004-03-17 | 2006-02-16 | Novartis Ag | Use of organic compounds |
US20060147520A1 (en) * | 2004-07-26 | 2006-07-06 | Curtis Ruegg | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
TW200628467A (en) | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
BRPI0610187B8 (pt) * | 2005-05-17 | 2021-05-25 | Actelion Pharmaceuticals Ltd | tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
SI1928409T1 (sl) | 2005-09-12 | 2012-12-31 | Actelion Pharmaceuticals Ltd. | Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid |
EP2351569B1 (fr) | 2005-10-26 | 2012-08-22 | Asahi Kasei Pharma Corporation | Fasudil dans des thérapies combinées pour le traitement de l'hypertension artérielle pulmonaire |
EP2111863B1 (fr) | 2005-10-26 | 2012-03-28 | Asahi Kasei Pharma Corporation | Combinaison du fasudil et bosentan pour le traitement de l'hypertension artérielle pulmonaire |
WO2007106494A2 (fr) * | 2006-03-13 | 2007-09-20 | Encysive Pharmaceuticals, Inc. | Procedes et compositions pour le traitement d'une insuffisance cardiaque diastolique |
CA2644784A1 (fr) * | 2006-03-13 | 2007-09-20 | Jinling Chen | Formulations de sitaxsentan sodium |
BRPI0709950A2 (pt) * | 2006-04-13 | 2011-08-02 | Actelion Pharmaceuticals Ltd | uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin |
US20080026061A1 (en) * | 2006-06-22 | 2008-01-31 | Reichwein John F | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide |
KR101149274B1 (ko) | 2006-07-20 | 2012-05-29 | 노파르티스 아게 | Cετρ 억제제로서의 아미노-피페리딘 유도체 |
AR062501A1 (es) * | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
US8071596B2 (en) | 2007-01-12 | 2011-12-06 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
AU2008232425A1 (en) * | 2007-04-02 | 2008-10-09 | Auspex Pharmaceuticals, Inc. | Substituted pyrimidines |
EP2150547A2 (fr) * | 2007-05-08 | 2010-02-10 | Generics Ýuk¨Limited | Nouvelles formes polymorphes |
WO2009004374A1 (fr) * | 2007-06-29 | 2009-01-08 | Generics [Uk] Limited | Procédé d'introduction d'une chaîne latérale hydroxyéthoxy dans le bosentan |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
US20090069351A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched bosentan |
WO2009047637A1 (fr) * | 2007-10-11 | 2009-04-16 | Actavis Group Ptc Ehf | Nouveaux polymorphes de bosentan |
NZ585438A (en) * | 2007-10-24 | 2012-09-28 | Generics Uk Ltd | Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide |
PE20090982A1 (es) | 2007-11-05 | 2009-08-13 | Novartis Ag | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) |
EP2229356B1 (fr) | 2007-12-03 | 2011-10-12 | Novartis AG | Dérivés de 4-benzylaminopyrrolidine 1,2-disubstituée comme inhibiteurs de cetp utiles pour le traitement de maladies telles que l'hyperlipidémie ou l'artériosclérose |
EP2072503B1 (fr) * | 2007-12-18 | 2011-10-26 | Dipharma Francis S.r.l. | Procédé de préparation de bosentan |
AU2009203174B2 (en) * | 2008-01-01 | 2014-01-30 | Cipla Limited | Method of synthesis of bosentan, its polymorphic forms and its salts |
WO2009095933A2 (fr) * | 2008-01-10 | 2009-08-06 | Msn Laboratories Limited | Procédé perfectionné et nouveau pour la préparation de bosentan |
EP2240469A2 (fr) * | 2008-01-24 | 2010-10-20 | Actavis Group PTC EHF | Forme cristallisée stable et sensiblement pure de bosentan |
US8785461B2 (en) | 2008-02-08 | 2014-07-22 | Generics [Uk] Limited | Process for preparing bosentan |
CN101279948B (zh) * | 2008-03-14 | 2010-08-11 | 苏州博鸿化工技术有限公司 | 4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法 |
WO2009141167A1 (fr) * | 2008-05-23 | 2009-11-26 | Synthon B.V. | Sels de bosentan |
US20110251220A1 (en) * | 2008-06-03 | 2011-10-13 | Acikgoez Oezlem | Pharmaceutical compositions comprising gamma secretase modulators |
WO2010012637A1 (fr) * | 2008-08-01 | 2010-02-04 | Inke, S.A. | Procédé de préparation du bosentan |
WO2010015623A1 (fr) * | 2008-08-05 | 2010-02-11 | Farmaprojects, S. A. | Procédé pour la fabrication d'antagonistes des récepteurs de l'endothéline |
WO2010032261A1 (fr) * | 2008-08-12 | 2010-03-25 | Cadila Healthcare Limited | Procédé pour la préparation de bosentan |
US8975402B2 (en) | 2008-11-03 | 2015-03-10 | Generics [Uk] Limited | HPLC method for the analysis of bosetan and related substances and use of these substances as reference standards and markers |
IT1393136B1 (it) * | 2009-03-11 | 2012-04-11 | Sifa Vitor S R L | Procedimento per la preparazione del bosentan |
US20100256371A1 (en) * | 2009-04-02 | 2010-10-07 | Glenmark | Processes for the preparation of bosentan and its intermediates thereof |
MX2011010817A (es) | 2009-04-13 | 2012-01-27 | Sandoz Ag | Proceso para preparacion de antagonista de receptor endotelial (bosentan). |
MX2011012199A (es) | 2009-05-15 | 2011-12-08 | Novartis Ag | Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. |
WO2010130796A1 (fr) | 2009-05-15 | 2010-11-18 | Novartis Ag | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase |
EA201101672A1 (ru) | 2009-05-28 | 2012-06-29 | Новартис Аг | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина |
BRPI1011657A2 (pt) | 2009-05-28 | 2019-04-16 | Novartis Ag | derivados aminopropiônicos substituídos como inibidores de neprilisina |
WO2011024056A2 (fr) | 2009-08-27 | 2011-03-03 | Aurobindo Pharma Limited | Procédé perfectionné pour la préparation de bosentan |
EP2499131A2 (fr) | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Formes cristallines du sel de bosentan et leurs procédés de préparation |
JP5654608B2 (ja) | 2009-11-17 | 2015-01-14 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
ES2472446T3 (es) | 2009-11-30 | 2014-07-01 | Novartis Ag | Derivados de imidazol como inhibidores de aldosterona sintasa |
US20120283190A1 (en) | 2009-12-09 | 2012-11-08 | Institut National de la Santé et de la Recherche Medicale (INSERM) | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
EP2368884A1 (fr) | 2010-03-25 | 2011-09-28 | Laboratorios Lesvi, S.L. | Procédé pour la préparation de bosentan |
JP5850576B2 (ja) * | 2010-07-06 | 2016-02-03 | 富士化学工業株式会社 | ボセンタン固体分散体 |
WO2012020421A1 (fr) | 2010-08-11 | 2012-02-16 | Megafine Pharma (P) Ltd. | Nouveau procédé de préparation de bosentan |
ES2714754T3 (es) * | 2010-10-01 | 2019-05-29 | Zach System Spa | Proceso para preparar monohidrato de bosentán y sus productos intermedios |
WO2012056468A1 (fr) | 2010-10-13 | 2012-05-03 | Matrix Laboratories Ltd | Procédé pour la préparation de bosentan |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
WO2012073135A1 (fr) | 2010-12-03 | 2012-06-07 | Alembic Pharmaceuticals Limited | Procédé amélioré de préparation de bosentan |
ES2386173B1 (es) * | 2011-01-13 | 2013-06-25 | Urquima, S.A. | Proceso de preparación de un antagonista del receptor de la endotelina |
EP2696857A1 (fr) | 2011-04-11 | 2014-02-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Composition pharmaceutique comprenant du bosentan |
WO2012159456A1 (fr) * | 2011-05-23 | 2012-11-29 | 昂科生物医学技术(苏州)有限公司 | Inhibiteur de cdc42 et ses utilisations |
WO2013098577A1 (fr) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions pharmaceutiques de bosentan |
US20130245259A1 (en) | 2012-03-16 | 2013-09-19 | Natco Pharma Limited | Process for the preparation of bosentan monohydrate |
ITMI20120701A1 (it) | 2012-04-27 | 2013-10-28 | Dipharma Francis Srl | Procedimento per la purificazione di un composto benzensolfonammidico |
JP2015503555A (ja) | 2012-05-11 | 2015-02-02 | ハナル・バイオファーマ・カンパニー・リミテッド | ボセンタン制御放出性経口製剤 |
WO2013186706A1 (fr) | 2012-06-12 | 2013-12-19 | Cadila Pharmaceuticals Ltd | Procédé pour la préparation de bosentan |
US9296705B2 (en) | 2012-08-31 | 2016-03-29 | Davuluri Ramamohan Rao | 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2(2-pyrimidinyl)-pyrimidine-4-yl)-benzen esulfonamide sodium |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
KR102004422B1 (ko) | 2012-12-20 | 2019-07-26 | 제일약품주식회사 | 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법 |
LT2956464T (lt) | 2013-02-14 | 2018-07-10 | Novartis Ag | Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai |
US9340582B2 (en) | 2013-07-25 | 2016-05-17 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
MX2016001020A (es) | 2013-07-25 | 2016-08-03 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca. |
CN103554037B (zh) * | 2013-11-08 | 2015-03-18 | 南京靖龙药物研发有限公司 | 一种波生坦代谢物羟基波生坦的制备方法 |
AU2016209968B2 (en) | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
ES2584534B1 (es) | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
WO2018185516A1 (fr) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques destinées à traiter une toxicité cardiovasculaire induite par une thérapie anticancéreuse |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
TWI833430B (zh) * | 2021-11-08 | 2024-02-21 | 大陸商正大天晴藥業集團股份有限公司 | 氮雜聯苯類化合物及其應用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1545944A1 (de) * | 1964-06-19 | 1969-12-11 | Hoffmann La Roche | Verfahren zur Herstellung von neuen Sulfonamiden der Pyrimidinreihe |
AU6623690A (en) * | 1990-10-29 | 1992-05-26 | Ibrahim Raouf Shimi | Novel sulfamide derivatives, a method for obtaining them and their use as a drug |
-
1992
- 1992-01-31 RU SU925011139A patent/RU2086544C1/ru active Protection Beyond IP Right Term
- 1992-06-04 DK DK92109431T patent/DK0526708T3/da not_active Application Discontinuation
- 1992-06-04 ES ES92109431T patent/ES2152222T4/es not_active Expired - Lifetime
- 1992-06-04 DE DE59209872T patent/DE59209872D1/de not_active Expired - Lifetime
- 1992-06-04 EP EP92109431A patent/EP0526708B1/fr not_active Expired - Lifetime
- 1992-06-04 PT PT92109431T patent/PT526708E/pt unknown
- 1992-06-04 SG SG1996004376A patent/SG54209A1/en unknown
- 1992-06-04 DE DE10299047C patent/DE10299047I2/de active Active
- 1992-06-04 AT AT92109431T patent/ATE197044T1/de active
- 1992-06-05 ZA ZA924126A patent/ZA924126B/xx unknown
- 1992-06-09 NZ NZ243074A patent/NZ243074A/en not_active IP Right Cessation
- 1992-06-09 MX MX9202747A patent/MX9202747A/es active IP Right Grant
- 1992-06-09 IL IL10213892A patent/IL102138A/en active Protection Beyond IP Right Term
- 1992-06-09 US US07/896,015 patent/US5292740A/en not_active Expired - Lifetime
- 1992-06-09 AU AU18121/92A patent/AU653604B2/en not_active Expired
- 1992-06-10 DZ DZ920066A patent/DZ1587A1/fr active
- 1992-06-10 JP JP4174993A patent/JPH0730042B2/ja not_active Expired - Fee Related
- 1992-06-10 HU HU9201930A patent/HU221203B1/hu active Protection Beyond IP Right Term
- 1992-06-11 RO RO92-0780A patent/RO111268B/ro unknown
- 1992-06-12 FI FI922746A patent/FI112216B/fi active Protection Beyond IP Right Term
- 1992-06-12 CA CA002071193A patent/CA2071193C/fr not_active Expired - Lifetime
- 1992-06-12 IS IS3877A patent/IS2054B/is unknown
- 1992-06-12 CZ CS921804A patent/CZ281434B6/cs not_active IP Right Cessation
- 1992-06-12 SK SK1804-92A patent/SK279006B6/sk not_active IP Right Cessation
- 1992-06-12 KR KR1019920010205A patent/KR100235507B1/ko not_active IP Right Cessation
- 1992-06-12 NO NO922323A patent/NO303826B1/no not_active IP Right Cessation
- 1992-06-15 BR BR929202219A patent/BR9202219A/pt not_active Application Discontinuation
- 1992-07-01 IE IE192092A patent/IE921920A1/en active Protection Beyond IP Right Term
- 1992-11-18 TW TW081109235A patent/TW222625B/zh not_active IP Right Cessation
-
1994
- 1994-02-28 BG BG98607A patent/BG60831B2/bg unknown
- 1994-11-23 EE EE9400322A patent/EE03028B1/xx unknown
-
1995
- 1995-06-20 HU HU95P/P00261P patent/HU211683A9/hu unknown
-
2000
- 2000-12-28 GR GR20000402849T patent/GR3035162T3/el unknown
-
2001
- 2001-11-01 CY CY0100036A patent/CY2306B1/xx unknown
-
2002
- 2002-09-02 NL NL300097C patent/NL300097I1/nl unknown
- 2002-10-16 LU LU90976C patent/LU90976I2/fr unknown
- 2002-10-16 LU LU90975C patent/LU90975I2/fr unknown
- 2002-10-29 NO NO2002012C patent/NO2002012I2/no unknown
-
2004
- 2004-10-27 CY CY2004005C patent/CY2004005I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK279006B6 (sk) | Substituované fenylsulfonylamidopyrimidíny, spôsob | |
KR100238366B1 (ko) | 설폰아미드 및 이를 함유하는 약제학적 제제 | |
KR100300503B1 (ko) | 설폰아미드,이의제조방법및이를함유하는약제 | |
EP0658548B1 (fr) | Dérivés de la benzènesulfonamide et procédé de préparation | |
EP0959072B1 (fr) | Dérivés de sulfonamide et procédé pour leur préparation | |
CZ287184B6 (en) | Sulfonylaminopyridines, process of their preparation and use as well as pharmaceutical preparations based thereon | |
HU225112B1 (en) | Sulfonamides substituted with heterocycle, pharmaceutical compositions containing them and process for their preparation | |
JP3067131B2 (ja) | 医薬組成物 | |
RU2083567C1 (ru) | Производные арилсульфонамида или их соли и фармацевтическая композиция, проявляющая ангиопротекторное, антигипертензивное и вазоспазмолитическое, в частности противоишемическое, действие | |
JP2790065B2 (ja) | ベンゼンスルホンアミド誘導体及びその製法 | |
SI9200268A (sl) | Uporaba sulfonamidov za pripravo zdravil in novi sulfonamidi | |
SA92130049B1 (ar) | سلفوناميدات sulphonamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Patent expired |
Expiry date: 20120612 |
|
SPCG | Grant of an spc |
Spc suppl protection certif: 27 5004-2004 Extension date: 20170828 |
|
QB4A | Licence contract registered or granted |
Free format text: SPC 27 5004-2004 Name of requester: F. HOFFMANN - LA ROCHE AG, CH Effective date: 20170802 |
|
SPCE | Expiry of an spc |
Spc suppl protection certif: 27 5004-2004 Extension date: 20170828 |